Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 4020937, 13 pages
https://doi.org/10.1155/2018/4020937
Review Article

Clinical Significance and Biological Role of HuR in Head and Neck Carcinomas

1First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
2Department of Pathology, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany
3Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK

Correspondence should be addressed to Ioly Kotta-Loizou; ku.ca.lairepmi@31uoziol-attok.i and Stamatios Theocharis; rg.aou.dem@oehtmats

Received 17 August 2017; Accepted 27 November 2017; Published 28 January 2018

Academic Editor: Michal Barak

Copyright © 2018 Georgia Levidou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Audic and R. Hartley, “Post-transcriptional regulation in cancer,” Biology of the Cell, vol. 96, no. 7, pp. 479–498, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Siomi and G. Dreyfuss, “RNA-binding proteins as regulators of gene expression,” Current Opinion in Genetics & Development, vol. 7, no. 3, pp. 345–353, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Wurth, “Versatility of RNA-binding proteins in cancer,” Comparative and Functional Genomics, vol. 2012, Article ID 178525, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Dalmau, H. M. Furneaux, R. J. Gralla, M. G. Kris, and J. B. Posner, “Detection of the anti-Hu antibody in serum of patients with small cell lung cancer-a quantitative western blot analysis,” Annals of Neurology, vol. 27, no. 5, pp. 544–552, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. W. J. Ma, S. Cheng, C. Campbell, A. Wright, and H. Furneaux, “Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein,” The Journal of Biological Chemistry, vol. 271, no. 14, pp. 8144–8151, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Farber, “The multistep nature of cancer development,” Cancer Research, vol. 44, pp. 4217–4225, 1984. View at Google Scholar
  7. L. Licitra, J. Bernier, C. Grandi et al., “Cancer of the larynx,” Critical Reviews in Oncology/Hematology, vol. 45, pp. 65–80, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Cabilla, S. I. Nudler, S. A. Ronchetti, F. A. Quinteros, M. Lasaga, and B. H. Duvilanski, “Nitric oxide-sensitive guanylyl cyclase is differentially regulated by nuclear and non-nuclear estrogen pathways in anterior pituitary gland,” PLoS One, vol. 6, no. 12, article e29402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. H. H. Woo, Y. Zhou, X. Yi et al., “Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer,” Oncogene, vol. 28, no. 9, pp. 1176–1186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Calaluce, M. M. Gubin, J. W. Davis et al., “The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer,” BMC Cancer, vol. 10, no. 1, p. 126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Kotta-Loizou, C. Giaginis, and S. Theocharis, “Clinical significance of HuR expression in human malignancy,” Medical Oncology, vol. 31, no. 9, p. 161, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Kotta-Loizou, S. N. Vasilopoulos, R. H. Coutts, and S. Theocharis, “Current evidence and future perspectives on HuR and breast cancer development, prognosis, and treatment,” Neoplasia, vol. 18, no. 11, pp. 674–688, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Kurosu, N. Ohga, Y. Hida et al., “HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium,” British Journal of Cancer, vol. 104, no. 5, pp. 819–829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Müller, “Update from the 4th edition of the World Health Organization of head and neck tumours: tumours of the oral cavity and mobile tongue,” Head and Neck Pathology, vol. 11, no. 1, pp. 33–40, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Gale, M. Poljak, and N. Zidar, “Update from the 4th edition of the World Health Organization classification of head and neck tumours: what is new in the 2017 WHO blue book for tumours of the hypopharynx, larynx, trachea and parapharyngeal space,” Head and Neck Pathology, vol. 11, no. 1, pp. 23–32, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. E. B. Stelow and B. M. Wenig, “Update from the 4th edition of the World Health Organization classification of head and neck tumours: nasopharynx,” Head and Neck Pathology, vol. 11, no. 1, pp. 16–22, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. E. B. Stelow and J. A. Bishop, “Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the nasal cavity, paranasal sinuses and skull base,” Head and Neck Pathology, vol. 11, no. 1, pp. 3–15, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. W. H. Westra and J. S. Lewis Jr., “Update from the 4th edition of the World Health Organization classification of head and neck tumours: oropharynx,” Head and Neck Pathology, vol. 11, no. 1, pp. 41–47, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Katabi and J. S. Lewis, “Update from the 4th edition of the World Health Organization classification of head and neck tumours: what is new in the 2017 WHO blue book for tumors and tumor-like lesions of the neck and lymph nodes,” Head and Neck Pathology, vol. 11, no. 1, pp. 48–54, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Kakuguchi, T. Kitamura, T. Kuroshima et al., “HuR knockdown changes the oncogenic potential of oral cancer cells,” Molecular Cancer Research, vol. 8, no. 4, pp. 520–528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. W. J. Ma and H. Furneaux, “Localization of the human HuR gene to chromosome 19p13.2,” Human Genetics, vol. 99, no. 1, pp. 32-33, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. C. G. Burd and G. Dreyfuss, “Conserved structures and diversity of functions of RNA-binding proteins,” Science, vol. 265, no. 5172, pp. 615–621, 1994. View at Publisher · View at Google Scholar
  24. S. Govindaraju and B. S. Lee, “Adaptive and maladaptive expression of the mRNA regulatory protein HuR,” World Journal of Biological Chemistry, vol. 4, no. 4, pp. 111–118, 2013. View at Publisher · View at Google Scholar
  25. X. C. Fan and J. A. Steitz, “HNS, a nuclear-cytoplasmic shuttling sequence in HuR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15293–15298, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. V. E. Myer, X. C. Fan, and J. A. Steitz, “Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay,” The EMBO Journal, vol. 16, no. 8, pp. 2130–2139, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. X. C. Fan and J. A. Steitz, “Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs,” The EMBO Journal, vol. 17, no. 12, pp. 3448–3460, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. S. S. Peng, C. Y. Chen, N. Xu, and A. B. Shyu, “RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein,” The EMBO Journal, vol. 17, no. 12, pp. 3461–3470, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Kullmann, U. Gopfert, B. Siewe, and L. Hengst, “ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5UTR,” Genes & Development, vol. 16, no. 23, pp. 3087–3099, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Mazan-Mamczarz, S. Galban, I. Lopez de Silanes et al., “RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8354–8359, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Zhu, H. L. Zhou, R. A. Hasman, and H. Lou, “Hu proteins regulate polyadenylation by blocking sites containing U-rich sequences,” The Journal of Biological Chemistry, vol. 282, no. 4, pp. 2203–2210, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. Meng, P. H. King, L. B. Nabors et al., “The ELAV RNA-stability factor HuR binds the 5-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation,” Nucleic Acids Research, vol. 33, no. 9, pp. 2962–2979, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. C. H. Yeh, L. Y. Hung, C. Hsu et al., “RNA-binding protein HuR interacts with thrombomodulin 5untranslated region and represses internal ribosome entry site-mediated translation under IL-1β treatment,” Molecular Biology of the Cell, vol. 19, no. 9, pp. 3812–3822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Durie, M. Hatzoglou, P. Chakraborty, and M. Holcik, “HuR controls mitochondrial morphology through the regulation of BclxL translation,” Translation, vol. 1, article e23980, 2013. View at Publisher · View at Google Scholar
  35. A. Rivas-Aravena, P. Ramdohr, M. Vallejos et al., “The Elav-like protein HuR exerts translational control of viral internal ribosome entry sites,” Virology, vol. 392, no. 2, pp. 178–185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Y. Lin, G. Brewer, and M. L. Li, “HuR and Ago2 bind the internal ribosome entry site of enterovirus 71 and promote virus translation and replication,” PLoS One, vol. 10, no. 10, article e0140291, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Izquierdo, “Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition,” Journal of Biological Chemistry, vol. 283, no. 27, pp. 19077–19084, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Mukherjee, D. L. Corcoran, J. D. Nusbaum et al., “Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability,” Molecular Cell, vol. 43, no. 3, pp. 327–339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Akaike, K. Masuda, Y. Kuwano et al., “HuR regulates alternative splicing of the TRA2β gene in human colon cancer cells under oxidative stress,” Molecular and Cellular Biology, vol. 34, no. 15, pp. 2857–2873, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Abdelmohsen, A. Lal, H. H. Kim, and M. Gorospe, “Posttranscriptional orchestration of an anti-apoptotic program by HuR,” Cell Cycle, vol. 6, no. 11, pp. 1288–1292, 2007. View at Publisher · View at Google Scholar
  41. A. Yiakouvaki, M. Dimitriou, I. Karakasiliotis, C. Eftychi, S. Theocharis, and D. L. Kontoyiannis, “Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis,” The Journal of Clinical Investigation, vol. 122, no. 1, pp. 48–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Khan, N. Khan, R. P. Tiwari, N. K. Sah, G. B. Prasad, and P. S. Bisen, “Biology of Cox-2: an application in cancer therapeutics,” Current Drug Targets, vol. 12, no. 7, pp. 1082–1093, 2011. View at Publisher · View at Google Scholar
  43. N. Ghosh, R. Chaki, V. Mandal, and S. C. Mandal, “COX-2 as a target for cancer chemotherapy,” Pharmacological Reports, vol. 62, no. 2, pp. 233–244, 2010. View at Publisher · View at Google Scholar
  44. N. P. Cho, H. S. Han, Y. Soh, K. Y. Lee, and H. J. Son, “Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas,” Pathology, vol. 39, no. 6, pp. 545–550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. J. L. Dean, G. Sully, R. Wait, L. Rawlinson, A. R. Clark, and J. Saklatvala, “Identification of a novel AU-rich-element-binding protein which is related to AUF1,” The Biochemical Journal, vol. 366, no. 3, pp. 709–719, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. D. A. Dixon, C. D. Kaplan, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott, “Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3-untranslated region,” The Journal of Biological Chemistry, vol. 275, no. 16, pp. 11750–11757, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Mazan-Mamczarz and R. B. Gartenhaus, “Post-transcriptional control of the MCT-1-associated protein DENR/DRP by RNA-binding protein AUF1,” Cancer Genomics & Proteomics, vol. 4, no. 3, pp. 233–239, 2007. View at Google Scholar
  48. L. B. Nabors, G. Y. Gillespie, L. Harkins, and P. H. King, “HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3 untranslated regions of cytokine and angiogenic factor mRNAs,” Cancer Research, vol. 61, no. 5, pp. 2154–2161, 2001. View at Google Scholar
  49. K. Abdelmohsen, S. Srikantan, Y. Kuwano, and M. Gorospe, “miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 51, pp. 20297–20302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. X. Guo, Y. Wu, and R. S. Hartley, “MicroRNA-125a represses cell growth by targeting HuR in breast cancer,” RNA Biology, vol. 6, no. 5, pp. 575–583, 2009. View at Publisher · View at Google Scholar
  51. V. Katsanou, O. Papadaki, S. Milatos et al., “HuR as a negative posttranscriptional modulator in inflammation,” Molecular Cell, vol. 19, no. 6, pp. 777–789, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Sengupta, B. C. Jang, W. MT, J. H. Paik, H. Furneaux, and T. Hla, “The RNA-binding protein HuR regulates the expression of cyclooxygenase-2,” The Journal of Biological Chemistry, vol. 278, no. 27, pp. 25227–25233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Wang, M. C. Caldwell, S. Lin, H. Furneaux, and M. Gorospe, “HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation,” The EMBO Journal, vol. 19, no. 10, pp. 2340–2350, 2000. View at Publisher · View at Google Scholar
  54. V. Lafarga, A. Cuadrado, I. Lopez de Silanes, R. Bengoechea, O. Fernandez-Capetillo, and A. R. Nebreda, “p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21Cip1 mRNA mediates the G1/S checkpoint,” Molecular and Cellular Biology, vol. 29, no. 16, pp. 4341–4351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Doller, A. Huwiler, R. Muller, H. H. Radeke, J. Pfeilschifter, and W. Eberhardt, “Protein kinase Cα-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2,” Molecular Biology of the Cell, vol. 18, no. 6, pp. 2137–2148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Yoon, K. Abdelmohsen, S. Srikantan et al., “Tyrosine phosphorylation of HuR by JAK3 triggers dissociation and degradation of HuR target mRNAs,” Nucleic Acids Research, vol. 42, no. 2, pp. 1196–1208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. M. N. Hinman and H. Lou, “Diverse molecular functions of Hu proteins,” Cellular and Molecular Life Sciences, vol. 65, no. 20, pp. 3168–3181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Doller, C. Winkler, I. Azrilian et al., “High-constitutive HuR phosphorylation at Ser 318 by PKCδ propagates tumor relevant functions in colon carcinoma cells,” Carcinogenesis, vol. 32, no. 5, pp. 676–685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Rebane, A. Aab, and J. A. Steitz, “Transportins 1 and 2 are redundant nuclear import factors for hnRNP A1 and HuR,” RNA, vol. 10, no. 4, pp. 590–599, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. C. M. Brennan, I. E. Gallouzi, and J. A. Steitz, “Protein ligands to HuR modulate its interaction with target mRNAs in vivo,” The Journal of Cell Biology, vol. 151, no. 1, pp. 1–14, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. I. E. Gallouzi, C. M. Brennan, and J. A. Steitz, “Protein ligands mediate the CRM1-dependent export of HuR in response to heat shock,” RNA, vol. 7, no. 9, pp. 1348–1361, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Higashino, M. Aoyagi, A. Takahashi et al., “Adenovirus E4orf6 targets pp32/LANP to control the fate of ARE-containing mRNAs by perturbing the CRM1-dependent mechanism,” The Journal of Cell Biology, vol. 170, no. 1, pp. 15–20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. J. D. Cha, S. Li, and I. H. Cha, “Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma,” Head & Neck, vol. 33, no. 5, pp. 627–637, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. J. D. Cha, H. K. Kim, and I. H. Cha, “Cytoplasmic HuR expression: correlation with cellular inhibitors of apoptosis protein-2 expression and clinicopathologic factors in oral squamous cell carcinoma cells,” Head & Neck, vol. 36, no. 8, pp. 1168–1175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. S. Hwang, K. K. Park, and W. Y. Chung, “Kalopanaxsaponin A inhibits the invasion of human oral squamous cell carcinoma by reducing metalloproteinase-9 mRNA stability and protein trafficking,” Biological and Pharmaceutical Bulletin, vol. 35, no. 3, pp. 289–300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Hasegawa, W. Kakuguchi, T. Kuroshima et al., “HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells,” British Journal of Cancer, vol. 100, no. 12, pp. 1943–1948, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Talwar, J. Jin, B. Carroll, A. Liu, M. B. Gillespie, and V. Palanisamy, “Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress,” Journal of Biological Chemistry, vol. 286, no. 37, pp. 32333–32343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Y. Kim, S. Li, J. D. Cha, X. Zhang, and I. H. Cha, “Significance of molecular markers in survival prediction of oral squamous cell carcinoma,” Head & Neck, vol. 34, no. 7, pp. 929–936, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. U. Habiba, T. Kitamura, A. Yanagawa-Matsuda et al., “Cytoplasmic expression of HuR may be a valuable diagnostic tool for determining the potential for malignant transformation of oral verrucous borderline lesions,” Oncology Reports, vol. 31, no. 4, pp. 1547–1554, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. U. Habiba, T. Kitamura, A. Yanagawa-Matsuda et al., “HuR and podoplanin expression is associated with a high risk of malignant transformation in patients with oral preneoplastic lesions,” Oncology Letters, vol. 12, no. 5, pp. 3199–3207, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Karrabul, J. Reibel, M. H. Therkildsen, F. Praetorius, H. W. Nielsen, and E. Dabelsteen, “Observer variability in the histologic assessment of oral premalignant lesions,” Journal of Oral Pathology & Medicine, vol. 24, no. 5, pp. 198–200, 1995. View at Publisher · View at Google Scholar
  72. L. M. Abbey, G. E. Kaugars, J. C. Gunsolley et al., “Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, vol. 80, no. 2, pp. 188–191, 1995. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Zhao, D. Sano, C. R. Pickering et al., “Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites,” Clinical Cancer Research, vol. 17, no. 23, pp. 7248–7264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. K. T. Lee, I. C. Sohn, H. J. Park, D. W. Kim, G. O. Jung, and K. Y. Park, “Essential moiety for antimutagenic and cytotoxic activity of hederagenin monodesmosides and bisdesmosides isolated from the stem bark of Kalopanax pictus,” Planta Medica, vol. 66, no. 04, pp. 329–332, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. H. J. Park, S. H. Kwon, J. H. Lee, K. H. Lee, K. Miyamoto, and K. T. Lee, “Kalopanaxsaponin A is a basic saponin structure for the anti-tumor activity of hederagenin monodesmosides,” Planta Medica, vol. 67, no. 2, pp. 118–121, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. S. S. Kumara and B. T. Huat, “Extraction, isolation and characterisation of antitumor principle, α-hederin, from the seeds of Nigella sativa,” Planta Medica, vol. 67, no. 1, pp. 29–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. I. Lopez de Silanes, A. Lal, and M. Gorospe, “HuR: post-transcriptional paths to malignancy,” RNA Biology, vol. 2, no. 1, pp. 11–13, 2005. View at Publisher · View at Google Scholar
  78. S. Niesporek, G. Kristiansen, A. Thoma et al., “Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression,” International Journal of Oncology, vol. 32, no. 2, pp. 341–347, 2008. View at Publisher · View at Google Scholar
  79. S. J. Lim, H. J. Kim, J. Y. Kim, K. Park, and C. M. Lee, “Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma,” International Journal of Gynecological Pathology, vol. 26, no. 3, pp. 229–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Mrena, J. P. Wiksten, A. Thiel et al., “Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR,” Clinical Cancer Research, vol. 11, no. 20, pp. 7362–7368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Denkert, W. Weichert, S. Pest et al., “Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression,” Cancer Research, vol. 64, no. 1, pp. 189–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. T. L. Erkinheimo, H. Lassus, A. Sivula et al., “Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma,” Cancer Research, vol. 63, no. 22, pp. 7591–7594, 2003. View at Google Scholar
  83. B. C. Jang, U. Munoz-Najar, J. H. Paik, K. Claffey, M. Yoshida, and T. Hla, “Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression,” The Journal of Biological Chemistry, vol. 278, no. 5, pp. 2773–2776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. L. Yang and X. M. Li, “The IAP family: endogenous caspase inhibitors with multiple biological activities,” Cell Research, vol. 10, no. 3, pp. 169–177, 2000. View at Publisher · View at Google Scholar
  85. S. J. Snipas, H. R. Stennicke, S. Riedl et al., “Inhibition of distant caspase homologues by natural caspase inhibitors,” The Biochemical Journal, vol. 357, no. 2, pp. 575–580, 2001. View at Publisher · View at Google Scholar
  86. L. JY and R. J. Schneider, “Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay,” The Journal of Biological Chemistry, vol. 279, pp. 12974–12979, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Ishimaru, S. Ramalingam, T. K. Sengupta et al., “Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells,” Molecular Cancer Research, vol. 7, no. 8, pp. 1354–1366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Y. Liu, Y. C. Liu, W. T. Huang, G. C. Huang, H. J. Su, and M. H. Lin, “Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas,” Journal of Oral Pathology & Medicine, vol. 36, no. 7, pp. 430–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. E. Vairaktaris, Z. Serefoglou, C. Yapijakis et al., “High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer,” Anticancer Research, vol. 27, no. 4B, pp. 2493–2498, 2007. View at Google Scholar
  90. H. Luukkaa, P. Klemi, P. Hirsimäki et al., “Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer,” Acta Oto-Laryngologica, vol. 128, no. 4, pp. 482–490, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nature Reviews Cancer, vol. 2, no. 3, pp. 161–174, 2002. View at Publisher · View at Google Scholar
  92. W. Wang, X. Yang, V. J. Cristofalo, N. J. Holbrook, and M. Gorospe, “Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence,” Molecular and Cellular Biology, vol. 21, no. 17, pp. 5889–5898, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Lal, K. Mazan-Mamczarz, T. Kawai, X. Yang, J. L. Martindale, and M. Gorospe, “Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs,” The EMBO Journal, vol. 23, no. 15, pp. 3092–3102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Santamaria, C. Barriere, A. Cerqueira et al., “Cdk1 is sufficient to drive the mammalian cell cycle,” Nature, vol. 448, no. 7155, pp. 811–815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Malumbres and M. Barbacid, “Cell cycle, CDKs and cancer: a changing paradigm,” Nature Reviews Cancer, vol. 9, no. 3, pp. 153–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Kim, K. Abdelmohsen, A. Lal et al., “Nuclear HuR accumulation through phosphorylation by Cdk1,” Genes & Development, vol. 22, no. 13, pp. 1804–1815, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Baldan, C. Mio, L. Allegri et al., “Identification of tumorigenesis-related mRNAs associated with RNA-binding protein HuR in thyroid cancer cells,” Oncotarget, vol. 7, no. 39, pp. 63388–63407, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Giaginis, P. Alexandrou, I. Delladetsima et al., “Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions,” Pathology & Oncology Research, vol. 22, no. 1, pp. 189–196, 2016. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Zheng and B. J. Baum, “Including the p53 ELAV-like protein-binding site in vector cassettes enhances transgene expression in rat submandibular gland,” Oral Diseases, vol. 18, no. 5, pp. 477–484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. N. P. Cho, H. S. Han, Y. Soh, and H. J. Son, “Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma,” Journal of Oral Pathology & Medicine, vol. 36, no. 5, pp. 297–303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. J. M. Donahue, E. T. Chang, L. Xiao et al., “The RNA-binding protein HuR stabilizes survivin mRNA in human oesophageal epithelial cells,” The Biochemical Journal, vol. 437, no. 1, pp. 89–96, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Vegran, R. Boidot, C. Oudin, C. Defrain, M. Rebucci, and S. Lizard-Nacol, “Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer,” Oncogene, vol. 26, no. 2, pp. 290–297, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. N. Filippova, X. Yang, Y. Wang et al., “The RNA-binding protein HuR promotes glioma growth and treatment resistance,” Molecular Cancer Research, vol. 9, no. 5, pp. 648–659, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. C. Hostetter, L. A. Licata, A. Witkiewicz et al., “Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells,” Cancer Biology & Therapy, vol. 7, no. 9, pp. 1496–1506, 2008. View at Publisher · View at Google Scholar · View at Scopus